INDIA
'Covaxin not water like': Bharat Biotech CEO lashes out at serum CEO, assures vaccine 200% safe
Hitting back at critics who targeted his company for not being transparent about vaccine trial data and receiving emergency use authorisation (EUA) for Covaxin even before trial end, he addressed the media via video-conferencing on Monday.
India record 20 more cases of UK coronavirus strain, total 58
Of these total cases, eight have been registered at the National Centre for Disease Control (NCDC), 11 at CSIR Institute of Genomics and Integrative Biology (IGIB), (both in Delhi), and 10 at National Institute of Mental Health and Neuro-Sciences (NIMHANS) in Bengaluru.
UK Covid-19 Variant: 3 more patients detected with mutant strain in Delhi's LNJP Hospital
Dr Suresh Kumar, Medical Director of Lok Nayak Jai Prakash (LNJP) Hospital informed that the three new cases were detected from a laboratory in Delhi. "The total number of patients suspected of being infected by the UK strain has reached 49. Of them, the strain is confirmed in the seven persons. Three new detections were reported from the Institute of Genomics and Integrative Biology (IGIB) in Delhi," he said.
Supreme Court clears Central Vista Project, including new Parliament building
The bench held that there were "no infirmities in clearances given, change in land use and the environmental clearances". However, it imposed some riders like clearance from heritage conservation committee. A bench comprising Justices A.M. Khanwilkar, Dinesh Maheshwari and Sanjiv Khanna said the heritage conservation committee's approval is needed before consruction begins and directed that the project proponents to get that approval.
Covaxin Controversy: Don't accuse us of inexperience, we are a global company, says Bharat Biotech
Bharat Biotech Chairman Krishna Ella said the company conducts clinical trials not only in India but also many other countries. His comments assume significance as Covaxin has been given an emergency approval despite allegedly only two of the required three trial phases being completed.
Residual terrorist strength in Kashmir currently below 200: MoD
Well synergised, intelligence-based operations have resulted in significant successes and have considerably degraded terrorist leadership and their capabilities in Jammu and Kashmir, the ministry said. Attempts to spread violence South of Pir Panjal Range have been comprehensively defeated by proactive operations. It is South of Pir Panjal Range from where terrorists from Pakistan make attempts to infiltrate in the valley.
Jack Ma's 'disappearance' may hit Indian firms in long run
According to US-based PitchBook that delivers data on private capital markets, Alibaba and its affiliates Alibaba Capital Partners and Ant Group (earlier known as Ant Financial) invested more than $2 billion in Indian companies since 2015. Overall, in the last five years, Chinese investors (including Tencent) have poured in over $5.7 billion into the Indian start-up ecosystem, according to data from Venture Intelligence.
China used 'unorthodox weapons', made unilateral attempts to change status quo at LAC: MoD
The ministry also pointed that Chinese made unilateral and provocative actions to change the status quo by force, in more than one area on the Line of Actual Control (LAC). India responded to it in a firm and non-escalatory way, ensuring the sanctity of our claims in Eastern Ladakh. "Indian Army has maintained all protocols and Agreements between the two countries while the PLA escalated the situation by utilisation of unorthodox weapons and amassing large number of troops," the ministry said.
Another Rs 6,000 cr released to states to meet GST compensation shortfall
Out of this, an amount of Rs 5,516.60 crore has been released to 23 states and an amount of Rs 483.40 crore has been released to the 3 Union Territories (UT) with Legislative Assembly (Delhi, Jammu & Kashmir & Puducherry) who are members of the GST Council.
Covaxin works against UK strain, will release study by January 10: Bharat Biotech CMD
CMD Dr Krishna Ella, addressing a virtual press conference, said: "We have taken 3-4 strains and studied it. It will come in publication on Medrevix on January 10. In a week's time, our confirmative data would come." Covaxin, India's indigenous COVID-19 vaccine by Bharat Biotech, is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio-containment facility.
Don't Miss
Advertisement